First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.

First-line immunotherapy-based standard of care and local ablative treatments for oligometastatic non-small cell lung cancer patients: a randomized, multicentre, open-label phase III study

Trial Details

NCT ID
NCT06840782
Phase
PHASE3
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Radical local treatment
  • SoC-based immunotherapy (+/- chemotherapy)
Locations (sample)
  • Creil, Hauts-de-France, France|49.25672,2.48477
  • Avignon, Provence-Alpes-Côte d'Azur Region, France|43.94834,4.80892
  • Villejuif, Île-de-France Region, France|48.7939,2.35992

Key Eligibility Criteria

  • Histologically proven advanced synchronous oligometastatic stage IV NSCLC.
  • NSCLC patients eligible first line immunotherapy-based SoC according to the European Marketing Authorization.
  • PDL1 status available.
  • Metastases eligible to RLT according to the local multidisciplinary board (MTB): ≤5cm each in CT scan, excluding primary tumour.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →